Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
AT&T Shares Drop to 30-Year Low
Shares of AT&T hit a 30-year low after reports showed thousands of lead-covered cables in several locations across the country. The Wall Street Journal reported on the story earlier in July.
Load More